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A signiﬁcant share of patients with phenylalanine hydroxylase (PAH) deﬁciency beneﬁts from pharmacological doses of tetrahydrobiop-
terin (BH4), the natural PAH cofactor. Phenylketonuria (PKU) is hypothesized to be a conformational disease, with loss of function due to
protein destabilization, and the restoration of enzyme function that is observed in BH4 treatment might be transmitted by correction of
protein misfolding. To elucidate the molecular basis of functional impairment in PAH deﬁciency, we investigated the impact of ten PAH
gene mutations identiﬁed in patients with BH4-responsiveness on enzyme kinetics, stability, and conformation of the protein (F55L,
I65S, H170Q, P275L, A300S, S310Y, P314S, R408W, Y414C, Y417H). Residual enzyme activity was generally high, but allostery was dis-
turbed in almost all cases and pointed to altered protein conformation. This was conﬁrmed by reduced proteolytic stability, impaired
tetramer assembly or aggregation, increased hydrophobicity, and accelerated thermal unfolding—with particular impact on the regula-
tory domain—observed in most variants. Three-dimensional modeling revealed the involvement of functionally relevant amino acid
networks that may communicate misfolding throughout the protein. Our results substantiate the view that PAH deﬁciency is a pro-
tein-misfolding disease in which global conformational changes hinder molecular motions essential for physiological enzyme function.
Thus, PKU has evolved from a model of a genetic disease that leads to severe neurological impairment to a model of a treatable protein-
folding disease with loss of function.Introduction
Deﬁciency of phenylalanine hydroxylase (PAH; EC
1.14.16.1) causes phenylketonuria (PKU [MIM 261600])
and is themost common inborn error of amino acidmetab-
olism in European-descended populations. Since the intro-
duction of a dietary treatment ﬁfty years ago, PKU has been
the prototype for a treatable genetic disease and, later, for
genetic screening inhumanpopulations.1 The recent recog-
nition of a new pharmacologically treatable phenotype of
PAH deﬁciency challenged the classical view of hereditary
diseases that result in loss of enzyme function. We previ-
ously showed that a signiﬁcant share of PKU patients re-
sponds to oral administration of the natural PAH cofactor
(tetrahydrobiopterin, BH4) although these individuals do
not display biochemical evidence of BH4 deﬁciency. The
treatment reduces blood phenylalanine concentrations,
restores enzyme activity in vivo, and signiﬁcantly increases
dietary-protein tolerance.2 Some authors proposed that
restoration of enzyme function observed under treatment
with pharmacological doses of BH4 is transmitted by correc-
tion of PAH misfolding.2–5
About 80% of all mutations in the PAH gene are
missense, and experimental data on the conformational
impact of single amino acid replacements on allostery, sta-
bility, and folding of the PAH protein is scarce. Because the
crystal structure of full-length PAH has not yet been com-
pletely solved,6–8 a composite model is commonly usedfor 3D structural analysis.9 PAH is a homotetrameric
enzyme, with each subunit composed of three functional
domains: the N-terminal regulatory domain (residues
1–142); the catalytic domain (residues 143–410), which
includes binding sites for substrate and cofactor; and the
oligomerization domain at the C terminus (residues 411–
452). There is a high degree of structural interplay between
the single domains and the subunits, respectively.6–8,10–13
Substrate (L-phenylalanine) and cofactor binding induce
conformational changes, which are transmitted through
networks of side-chain interactions.14,15 This is the basis
for homotropic allostery that allows for ﬁne-tuned regula-
tion of PAH enzyme activity comprising substrate activa-
tion, modulation of oligomerization, and the afﬁnity to
substrate and cofactor.3,4,12,15 We hypothesized that the
structural ﬂexibility of PAH permits gross conformational
changes required for enzyme function and thus renders
the enzyme susceptible to protein misfolding. This view
was supported by previous studies demonstrating dis-
turbed oligomerization and accelerated degradation of
some variant PAH proteins.3,4,16–19 However, only little is
known about the structural mechanisms leading to loss
of function in phenylketonuria and in other inherited
diseases that exhibit loss-of-function pathogenesis.
The aim of this study, therefore, was to elucidate the
molecular basis of loss of function in PKU. The impact of
single side-chain replacements associated with BH4-re-
sponsiveness on function and conformational stability of1Department of Molecular Pediatrics, Children’s Research Center, Dr. von Hauner Children’s Hospital, Ludwig Maximilians University, 80337 Munich,
Germany; 2Department of Medical Genetics, Molecular and Clinical Pharmacology, Innsbruck Medical University, 6020 Innsbruck, Austria; 3Department
of Clinical Chemistry and Clinical Biochemistry, Surgical Clinic, Ludwig Maximilians University, 80337 Munich, Germany
*Correspondence: ania.muntau@med.uni-muenchen.de
DOI 10.1016/j.ajhg.2008.05.013. ª2008 by The American Society of Human Genetics. All rights reserved.The American Journal of Human Genetics 83, 5–17, July 2008 5
the PAH protein was analyzed on the basis of enzyme
kinetics, oligomerization, limited proteolysis, thermal in-
activation, thermal unfolding, and 3D structural model-
ing. The mutations analyzed in this study caused pleiotro-
pic effects. Residual enzyme activity was generally high,
but allostery was disturbed in almost all cases and pointed
to altered protein conformation. Reduced proteolytic
stability of most variants, impaired tetramer assembly or
aggregation, increased hydrophobicity, and accelerated
thermal unfolding with particular impact on the regula-
tory domain corroborated the hypothesis of protein mis-
folding. To explain the remote effects on structure and
function that were observed, we propose a model of pro-
tein misfolding as communicated throughout the protein
by disruption of functional networks due to single amino
acid replacements.
In the past twenty years, scientists have made signiﬁcant
efforts to identify a consistent relationship between the
PAH genotype, in vitro residual enzyme activities, and
the clinical phenotype.20–22 A recent report from Pey and
colleagues in this journal marked a breakthrough by open-
ing the view on global conformation of PAH.23 Using com-
putational analyses, they predicted conclusive correlations
between the mutational energetic impact on the protein
and the clinical phenotype. Our results now provide exper-
imental evidence and new insights into how PAHmissense
mutations induce conformational protein destabilization
and loss of PAH function.
Material and Methods
Subjects and Mutations
In a previous study, we identiﬁedﬁve unrelatedpatients bearing six
mutations in the PAH gene that have not yet been characterized in
vitro.2 Three individualswere classiﬁedashavingmildPKU(plasma
phenylalanine concentrations in the absence of treatment ex-
ceeded 600 mmol/l but do not reach values higher than 1200
Figure 1. Structural Localization of PAH Missense
Mutations Analyzed
The PAH monomer, shown as a ribbon representation, is com-
posed of three functional domains: the N-terminal regulatory
domain (residues 19–142, blue), the central catalytic domain
(residues 143–410, red), and the C-terminal oligomerization
domain (residues 411–452, green). The active-site iron (silver
sphere) and the cofactor (orange stick model) are shown.
Amino acid residues affected by mutations are shown as stick
models.
mmol/l): patient 1, a Turkish girl born to consanguineous par-
ents; patient 2, a German girl born to nonconsanguineous
parents; andpatient5, aTurkishboyborntoconsanguineouspar-
ents. Patient 3, a German girl, and patient 4, a female German
newborn, were classiﬁed as having mild hyperphenylalanine-
mia, with plasma phenylalanine concentrations consistently
below 600 mmol/l on an unrestricted diet. In all patients, hyper-
phenylalaninemia had been detected by newborn-screening
programs, and BH4-responsiveness was subsequently demon-
strated in an extended BH4-loading test.
2 BH4 deﬁciency due to ge-
netic disorders of biosynthesis or regeneration of the cofactor had
been ruled out in all cases by the determination of urinary pterins
and the activity of dihydropteridin reductase in erythrocytes. We
obtained written informed consent for genotyping from the fami-
lies. Mutations and clinical phenotypes of the individual patients
are summarized in Table S1. The structural localization of muta-
tions characterized in this study was mapped to the composite
model of a PAH monomer (Figure 1). The mutations were located
in the regulatory domain (F55L, I65S), in the catalytic domain
(H170Q, P275L, A300S, S310Y, P314S, R408W), or in the dimeriza-
tion motif of the oligomerization domain (Y414C, Y417H).
Plasmid Constructs and Site-Directed Mutagenesis
The cDNA of human phenylalanine hydroxylase (ESTclone obtained
from imaGenes, formerly RZPD, Germany) was cloned into the
pMAL-c2E expression vector (New England Biolabs) encoding an
N-terminal MBP (maltose-binding protein) tag and an enteroki-
nase cleavage site. PAH mutants were constructed with the use
of the QuikChange site-directed mutagenesis kit (Stratagene). Au-
thenticity of the mutagenesis was veriﬁed by DNA sequencing.
Expression and Puriﬁcation
Expression plasmids were transformed into E. coli DH5a. Bacteria
were grown to midexponential phase at 37C, and overexpression
of wild-type and variant MBP-PAH fusion proteins was induced
with 0.3 mM isopropylthio-b-D-galactoside (IPTG). MBP-PAH
fusion proteins were more prone to form high-molecular-weight
aggregates at two hours of induction than they were at longer in-
duction periods, but the relative recovery of the tetrameric and the
dimeric form was similar (own and previous observations24). To
avoid artiﬁcial formation of aggregated PAH, we chose an induc-
tion time of 20 hr. Proteins were puriﬁed on A¨KTAxpress (GE
Healthcare) at 4C by afﬁnity chromatography (amylose resin,
New England Biolabs) as described previously,25 followed by
size-exclusion chromatography with a HiLoad 16/60 Superdex
200 column (GE Healthcare). The isolated tetrameric fusion pro-
teins were collected, and protein concentrations were determined
spectrophotometrically with the use of the absorption coefﬁcient
A280,
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It was previously shown that the MBP tag does not signiﬁcantly
affect PAH enzyme activity, kinetic parameters, or the oligomeric
state of the protein.16,17,25–27 Moreover, a comparative analysis
of limited proteolysis, thermal inactivation, and thermal denatur-
ation with the fusion protein and the cleaved PAH protein
revealed no signiﬁcant difference (data not shown).
Analysis of Oligomerization
Oligomerization proﬁles were obtained by size-exclusion chroma-
tography, and peaks corresponding to aggregated forms, tetramers,
dimers, and monomers were determined with the use of LMW
and HMW gel-ﬁltration calibration kits (GE-Healthcare). Relative
amounts of the different oligomeric states were calculated by
deconvolution of the chromatograms with the use of the ACD/
ChromManager software (Advanced Chemistry Development).
Blue dextran was used for determination of the void volume
(V0, 45.3 ml).
PAH-Activity Assay
PAH activity was determined as previously described.25,28 Tetra-
meric wild-type or variant MBP-PAH (0.01 mg/ml) was preincu-
bated with the L-phenylalanine (L-Phe) substrate for 5 min at
25C in a standard reaction buffer containing 15 mM Na HEPES,
pH 7.3 and 1 mg/ml catalase. After the addition of 10 mM ferrous
ammonium sulfate and an additional incubation of 1 min, the
reaction was initiated with BH4 (6[R]-L-erythro-5,6,7,8-tetrahydro-
biopterin, Cayman Chemicals) stabilized in 2 mM dithiothreitol
(DTT). Kinetic parameters were determined at standard L-Phe con-
centration (1 mM) with variable cofactor concentrations (0–704.1
mM BH4) or at standard BH4 concentration (75 mM) and variable
L-Phe concentrations (0–1 mM), respectively. Because of early sub-
strate inhibition, L-Phe concentrations were restricted to 0–250 mM
for P314S and to 0–500 mM for Y414C and Y417H, respectively. To
determine the level of substrate activation, a preincubation with
the substrate was omitted and the reaction was triggered by simul-
taneous addition of 1 mM L-Phe and 75 mM BH4. All concentra-
tions mentioned refer to the ﬁnal concentration in a 100 ml
reaction mixture. The amount of the L-tyrosin (L-Tyr) product
formed after 1 min was measured by HPLC and assayed as tripli-
cates. Steady-state kinetic parameters of three independent exper-
iments were calculated by nonlinear regression analysis with the
use of GraphPad Prism 4.0c (GraphPad Software). Enzyme kinetic
parameters at variable substrate concentrations displayed cooper-
ativity and were calculated with the Hill equation. Enzyme kinetic
parameters at variable cofactor concentrations were calculated
with theMichaelis-Menten equation or with themodiﬁedMichae-
lis-Menten equation29 in the case of cofactor inhibition (WT,
F55L, I65S, P314S, Y417H). All experimental data were conﬁrmed
by repeated analyses of different protein puriﬁcations.
Limited Proteolysis by Proteinase K
The puriﬁed tetramericMBP-PAH fusion proteins of wild-type PAH
and its variant forms were digested with proteinase K at 37C
in a buffer containing 20 mM Na HEPES, 200 mM NaCl, and
38.4 mM DTT at pH 7.0. Stocks of proteinase K and MBP-PAH
were prepared in 20 mM Na HEPES, 200 mM NaCl, pH 7.0 at ﬁnal
concentrations of 1 mg/ml and 1 mg/ml, respectively, and mixed
at protease to substrate ratio of 1:5000 by weight. Proteolysis was
terminated at 5, 10, 15, 20, 30, 60, 90, and 120 min time points
by addition of the inhibitor phenylmethylsulphonyl ﬂuoride
(PMSF) at a ﬁnal concentration of 4 mM. The reaction mixtureswere subjected to SDS-PAGE under reducing conditions with
4%–12% gradient polyacrylamide gels (Invitrogen). The pattern
of proteolysis was monitored by immunoblotting. MBP-PAH
fusion proteins and their proteolytic fragments were detected by
mouse monoclonal anti-phenylalanine hydroxylase IgG1 (PH8,
Calbiochem, 1:2000 dilution) and alkaline phosphatase conju-
gated anti-mouse IgG (Promega, 1:7500 dilution). Bound anti-
bodies were visualized by chemiluminescence with the CDP-Star
substrate (Roche) for alkaline phosphatase. Chemiluminescence
was monitored with the DIANA III imaging system, and the result-
ing protein bands were quantiﬁed by AIDA-software (Raytest). The
densitometry data of quadruplicate assays of one protein puriﬁca-
tion were normalized to the band corresponding to intact MBP-
PAH fusion protein and analyzed by nonlinear curve ﬁtting of
single exponential function in the case of the fusion protein.
The formation of the PAH fragment upon cleavage of the fusion
protein and subsequent degradation of the PAH fragment was
determined by nonlinear curve ﬁtting of a double exponential
‘‘Bateman function’’:
Y ¼ C3 Ki
Ki  Ke3

eKe 3 t  eKi 3 t
in which Y is the amount of the PAH protein; C is the theoretical
amount of the MBP-PAH fusion protein; Ki and Ke are the rate
constants for invasion and elimination of the PAH fragment,
respectively; and t is the incubation time.
Thermal Inactivation
Thermal inactivation of wild-type and variantMBP-PAHwas deter-
mined by analysis of the decay of enzyme activity as a function
of temperature. Aliquots of protein (1 mg/ml) were incubated in
20mMNaHEPES, 200mMNaCl, pH 7.0 for 10 min at 22 different
temperatures ranging from 20C to 75C and then chilled on ice.
PAH enzyme activity was subsequently measured as described
above. Residual activities were normalized to initial enzyme activ-
ity without incubation. Data points were subjected to nonlinear
regression analysis, and midpoints of thermal inactivation (Tm)
at 50% residual activity observed in three independent experi-
ments were calculated with the use of GraphPad Prism 4.0c with
the Boltzmann sigmoidal ﬁt (GraphPad Software).
Thermal Denaturation
Fluorescence measurements were performed on a Cary Eclipse
ﬂuorescence spectrophotometer equipped with a temperature-
controlled Peltier multicell holder (Varian). Samples contained
MBP-PAH fusion proteins (6 mM PAH subunit) in 20 mM Na
HEPES, 200 mM NaCl, pH 7.0, 10 mM ferrous ammonium sulfate,
and 1 mM DTT. Thermal denaturation was monitored by the fol-
lowing of changes in 8-anilino-1-naphtalenesulfonic acid (ANS;
Sigma Aldrich)-ﬂuorescence emission (excitation at 395 nm and
emission at 500 nm, 5.0/10.0 nm slit widths). Thermal denatur-
ation was performed at a rate of 1.2C/min in a 25–85C range.
Thermal denaturation curves were obtained by the plotting of
ﬂuorescence intensities against temperature. The phase transitions
observed in three independent experiments were determined, and
the respective transition midpoints were calculated by differentia-
tion of the increasing part of the curves. Signiﬁcances for the
differences between the wild-type and the variants were calculated
by two-tailed Student’s t test. Thermal denaturation of the MBP
protein occurs at temperatures above 62C, as previously shown30
and conﬁrmed for this experimental setup. Therefore, MBPThe American Journal of Human Genetics 83, 5–17, July 2008 7
denaturation did not interfere with the unfolding curves of the
PAH protein for ANS ﬂuorescence.
Structural Analyses and Figure Preparation
A composite model of the 3D structure (PDB codes 1PAH, 1PHZ,
2PHM, 2PAH, 3PAH, 1J8T, and 1J8U) of tetrameric PAH was
constructed with the use of the DeepView/Swiss-PdbViewer.31 In
the presence of hydrogen atoms, H bonds were computed with
the following constraints: 1.2–2.76 A˚ distance, 120 angles.
When hydrogen atoms were absent, H bonds were computed
with the following constraints: 2.35–3.2 A˚ distance, 90 angles.
Figures were prepared with the use of Visual Molecular Dynamics
software.32
Figure 2. PAH Mutations in All Three Domains Can Lead to
Aggregation or Impaired Tetramer Assembly
Oligomerization profiles of wild-type and variant PAH were
determined by size-exclusion chromatography. Chromatograms
of variant PAH were normalized to the tetramer peak of the
wild-type. Arrows mark the elution volumes of soluble aggre-
gates (45 to 47 ml), tetramers (56 ml), dimers (63 ml), and
monomers (71 ml).
(A) Profiles of variants arising from mutations located in the
regulatory domain (R). I65S showed increased amounts of di-
mers, whereas F55L was almost exclusively eluted as tetramers.
(B) Profiles of variants arising from mutations located in the
catalytic domain (C). S310Y and R408W eluted as high-molec-
ular-weight aggregates without any detectable tetramers. The
variants H170Q, P275L, A300S, and P314S eluted mainly in
the tetrameric form. For P275L, two additional peaks of higher
molecular weight were detected.
(C) Profiles of variants arising from mutations mapping to the
dimerization motif of the oligomerization domain (O). Y417H
showed significant amounts of monomers and increased
amounts of dimers, whereas Y414C showed only tetramers.
Results
Disturbed Oligomerization Manifests
as Aggregation or Impaired Tetramer Assembly
Wild-type PAH and ten variant forms of PAH were puri-
ﬁed by afﬁnity chromatography with subsequent size-
exclusion chromatography, and oligomeric states were
quantiﬁed by deconvolution analysis (Figure 2 and
Table 1). Wild-type PAH was eluted mainly in the tetra-
meric form (86.2%), with a small amount of dimers
(13.8%). Five variant PAH proteins (F55L, H170Q,
A300S, P314S, Y414C) that mapped to all three
domains showed elution proﬁles similar to that of
wild-type with minor changes of the dimer-tetramer
equilibrium. The remaining variants displayed dis-
turbed oligomerization, with only one mutant residue
(Y417H) mapping to the oligomerization domain.
Impaired tetramer assembly was observed for the I65S
mutation located in the regulatory domain and the
Y417H mutation located in the dimerization motif
of the oligomerization domain. The I65S mutation
showed increased amounts of dimers (28.5%). This is
in line with previously reported observations for the I65T
substitution showing a shifted equilibrium of tetramers
and dimers and proneness to aggregation.18,33,34 For the
Y417H variant we observed an oligomerization proﬁle pre-
viously not described for recombinant variant PAH.We de-
tected a signiﬁcant amount of monomers (11.1%), with an
increased amount of dimers (17.7%) in relation to tetra-
mers (63.7%), and some aggregates (7.5%). Although the
residue Y414 is in close proximity to Y417, the variant
Y414C showed an oligomerization pattern resembling
that of the wild-type protein. This is in contrast to previous
studies that reported aggregate formation for Y414C.35
Two mutations located in the catalytic domain (S310Y,8 The American Journal of Human Genetics 83, 5–17, July 2008
R408W) resulted in formation of high-molecular-weight
aggregates (100%) without the occurrence of any tetra-
meric PAH, suggesting a severe folding defect. In addition,
the variant P275L also formed some aggregates (13.2%), of
which the largest fraction (82.2%) was the tetrameric form.
In summary, we observed disturbed oligomerization not
only for mutations located in the oligomerization domain
but also for mutations located in the two other domains.
Our results conﬁrm that PAHmutations can lead tomisfold-
ing, with aggregation and/or disturbed tetramer assembly.
Residual Enzyme Activity of Variant PAH is High,
but Allostery is Disturbed
Detailed analyses of steady-state kinetic parameters were
performed for all puriﬁed tetrameric PAH proteins (Table
2). Enzyme activity of variant PAH was reduced in compar-
ison to wild-type with respect to Vmax determined at vari-
able L-Phe concentrations. However, the reduction in activ-
ity was generally moderate (R50% residual activity), with
the exception of P314S (22% residual activity). For most of
the variant proteins analyzed, the afﬁnity of variant PAH to
its cofactor BH4 or to its substrate L-Phe was not reduced.
Only P275L showed decreased cofactor afﬁnity, with
a threefold increase in Km (65 mM). By contrast, the Km
values for A300S (17 mM) and Y414C (16 mM) were slightly
decreased. The afﬁnity to the substrate was not reduced but
was even increased for P275L and P314S, as shown by
decreased values for S0.5 (76 and 49 mM, respectively).
Tetrameric wild-type PAH displayed positive cooperativ-
ity for L-Phe binding (Hill coefﬁcient [h], 3.0) and substrate
activation (activation fold, 3.0). Notably, all but one of
the PAH variants showed alterations in allostery. Positive
cooperativity was reduced for all variant proteins except
H170Q. Most variants showed reduced substrate activa-
tion, ranging from a mild decrease (P275L and Y414C; ac-
tivation fold 2.3 and 2.0, respectively) to a near-complete
loss (F55L, I65S, P314S, and Y417H; activation fold 1.5,
1.0, 1.3, and 1.5, respectively).
Table 1. Quantitative Analysis of Wild-Type and Variant PAH
Oligomerization Profiles
Missense Mutation Aggregates Tetramers Dimers Monomers
WT 86.2 13.8
F55L 94.1 5.9
I65S 71.5 28.5
H170Q 94.8 5.2
P275L 13.2 82.2 4.6
A300S 2.4 87.0 10.6
S310Y 100
P314S 83.2 16.8
R408W 100
Y414C 92.5 7.5
Y417H 7.5 63.7 17.7 11.1
Relative amounts of the eluted fractions corresponding to different oligo-
meric states of wild-type (WT) and variant PAH proteins are given as per-
centages. The relative amounts were calculated by deconvolution analysis
of the size-exclusion chromatograms.Taken together, the results show that reduction in en-
zyme activity was moderate for most variant PAH proteins,
and only one variant showed reduced afﬁnity to the cofac-
tor. However, allostery was severely affected by mutations
in all three domains. This indicates that side-chain replace-
ments can induce global conformational changes, with
remote effects on PAH enzyme function.
Susceptibility to Proteinase K is Increased
Misfolded subunits and incorrectly assembled oligomeric
forms of proteins are more susceptible to degradation by
proteases in mammalian cells.5 Previous studies using a
transcription and translation system or the protease tryp-
sin showed that mutations in the PAH gene can lead to
decreased protein stability.3–5,18
In this study, we probed protein conformation of PAH by
limited proteolysis with proteinase K. Here, the proteolytic
event is predominantly governed by the stereochemistry
and ﬂexibility of the protein substrate and not by the spec-
iﬁcity of the protease.36 Because MBP was fused to the
N-terminal regulatory domain of PAH, we hypothesized
that altered folding of this domain could lead to increased
susceptibility of the linker region to proteolytic cleavage.
This was conﬁrmed by the ﬁnding that the half-life of
the fusion protein was decreased by R 50% for six out of
eight MBP-PAH variants. Stability of the PAH fragment
was also decreased in most cases (Table 3). Mutations in
the regulatory domain and the oligomerization domain
led to minor reductions of PAH half-life, whereas severe
destabilization was detected for three mutations of the
catalytic domain (H170Q, P275L, A300S; 60%, 55%, and
50% of the wild-type, respectively). Interestingly, one cat-
alytic mutation (P314S) did not lead to destabilization
but even induced marked stabilization of both the fusion
protein (167%) and the PAH fragment (143%) in compari-
son to that of the wild-type.
The increased susceptibility to proteinase K observed
here is in line with the hypothesis that PAH destabilization
is due to partial protein unfolding.
Protein Unfolding Predominantly Affects
the Regulatory Domain of the Protein
To directly investigate whether variant PAH is prone to
aberrant folding, we analyzed conformational alterations
in the ground state and upon thermal denaturation. Two
distinct transitions were previously described for the
denaturation of wild-type PAH. These form the basis for
a three-stage model of thermal PAH denaturation: (i) a
low-temperature transition representing unfolding of the
four regulatory domains, (ii) a high-temperature transition
representing unfolding of two catalytic domains, and (iii)
irreversible protein denaturation.37
Thermal protein denaturation was analyzed by ANS ﬂuo-
rescence (Figures 3A, 3B, and 3C). Transition midpoints are
summarized in Table 4. The usage of the hydrophobic ﬂuo-
rophoreANSallowedus tomonitoroverall unfoldingevents
because it binds to hydrophobic groups of the denaturingThe American Journal of Human Genetics 83, 5–17, July 2008 9
Table 2. Enzyme Kinetic Parameters
L-Phea BH4
b
Missense Mutation Vmax
e (nmol L-Tyr/min 3 mg protein) [S]0.5
e (mM) h Activation Fold Vmax
e (nmol L-Tyr/min 3 mg protein) Km
e (mM)
WT 3470575 15556 3.0 3.0 34255 139 245 3
F55L 2088566 12859 1.5 1.5 24085 112 225 3
I65S 22145130 168520 1.4 1.0 37625 152 295 3
H170Q 2174537 12554 3.1 3.6 21975 43 255 2
P275L 1706525 7653 1.6 2.3 32165 67 655 4
A300S 2990564 14856 2.4 3.7 33205 58 175 2
P314Sc 780522 4952 1.9 1.3 7605 39 255 4
Y414Cd 1877551 104540 2.2 2.0 18705 50 165 2
Y417Hd 2258554 135540 2.5 1.5 28665 188 315 4
Steady-state kinetic parameters of wild-type (WT) and variant tetrameric MBP-PAH fusion proteins. Activation fold represents the substrate activation as
the ratio of specific activity with and without prior incubation with L-Phe. Apparent affinities for L-Phe ([S]0.5) and BH4 (Km) and the Hill-coefficient (h) as
a measure of cooperativity are shown.
a Enzyme kinetic parameters determined at variable L-Phe concentrations and standard BH4 concentration in three independent experiments.
b Enzyme kinetic parameters determined at variable BH4 concentrations and standard L-Phe concentration in three independent experiments.
c
L-Phe concentrations restricted to 0–250 mM.
d
L-Phe concentrations restricted to 0–500 mM.
e Values are given as means5 SEM.protein and shows a high quantum yield in its bound state
butnotwhensolved in aqueousbuffers.38ANS-ﬂuorescence
analysis of tetrameric wild-type PAH fusion proteins re-
vealed a low-temperature transitionandahigh-temperature
transition, with their respective midpoints at 47.3C and
55.0C. This is in agreement with previous results obtained
by differential scanning calorimetry.37
The two mutations located in the regulatory domain
(F55L, I65S) induced alterations in unfolding patterns.
An elevated ﬂuorescence signal for I65S in comparison to
wild-type was detected in the ground state at 25C. This in-
dicates an increased hydrophobicity due to partial protein
unfolding. The same was true to a minor extent for F55L.
Table 3. Proteolytic Stability of Wild-Type and Variant PAH
Missense
Mutation
t1/2 FP
(% of WT) SEM p Value
t1/2 PAH
(% of WT) SEM p Value
WT 100 100
F55L 71 7 0.039 75 15 ns
I65S 34 7 0.001 85 17 ns
H170Q 26 5 0.001 60 12 0.003
P275L 40 4 0.001 55 16 0.002
A300S 31 9 0.001 50 16 0.001
P314S 167 10 0.013 143 16 0.019
Y414C 47 13 0.004 70 16 0.017
Y417H 52 4 0.003 86 18 ns
Stability of wild-type (WT) and variant PAH against limited proteolysis by
proteinase K. Degradation of the MBP-PAH fusion protein and formation
with subsequent degradation of the PAH fragment were probed by west-
ern-blotting analyses. Densitometry data were normalized to intact
MBP-PAH fusion protein and the resulting data points were fitted by single
exponential function (MBP-PAH fusion proteins) and by double exponential
Bateman function (PAH fragment). The calculated half-lives of fusion pro-
teins (t1/2 FP) and of PAH fragments (t1/2 PAH) are given in percent5 SEM
of n ¼ 4 independent experiments. Significances for the differences
between wild-type and the variants were calculated by two-tailed Student’s
t test.10 The American Journal of Human Genetics 83, 5–17, July 2008During thermal unfolding, F55L showed a left-shift of
the low-temperature transition in comparison with the
wild-type protein (tm1/2 43.7
C), whereas a complete loss
of the low-temperature transition was observed for I65S.
By contrast, neither F55L nor I65S signiﬁcantly affected
the high-temperature transition. These ﬁndings indicate
that the two mutations located in the regulatory domain
inducedmisfolding and facilitated unfolding of the respec-
tive domain but did not inﬂuence the conformational
stability of the catalytic domain.
Thermal unfolding of variant PAH was also affected by
the four mutations located in the catalytic domain. All var-
iants but P275L showed elevated ground-state levels of
ANS ﬂuorescence. All residue substitutions in the catalytic
domain induced a left-shift of the low-temperature transi-
tion that reached statistical signiﬁcance for A300S (tm1/2
44.6C) and P275L (tm1/2 44.1C). Interestingly, none of
the mutations located in the catalytic domain signiﬁcantly
altered the high-temperature transition, indicating that
these mutations did not affect unfolding of the catalytic
domain itself but induced a loss of structural integrity of
the regulatory domain.
Distinct alterations of thermal-unfolding parameters
were observed for the two mutations located in the oligo-
merization domain (Y414C, Y417H). In contrast to other
variants exhibiting accelerated thermal unfolding, the
ground-state ANS ﬂuorescence of Y414C and Y417H re-
mained unchanged. However, the low-temperature transi-
tion was considerably left-shifted for Y414C (tm1/2 43.1
C)
and for Y417H (tm1/2 41.9
C), whereas no effect on the
high-temperature transition was detected. The residues
Y414 and Y417 are located close to the site of interaction
between the oligomerization domain and the regulatory
domain within one PAH subunit. This might explain the
effect of these side-chain replacements on the stability of
the regulatory domain.
To assess the impact of thermal stress on PAH enzyme
activity, we performed thermal-inactivation assays (Fig-
ure 3D). A reduction of the thermal-inactivationmidpoints
at 50% residual activity (Tm) in comparison to the wild-
type protein (48.8C) was observed for three variants
(I65S, P314S, Y417H, Tm; 46.2, 44.5, and 45.0
C, respec-
tively), whereas thermal inactivation of the other variants
was not altered (Table 4). The affected residues mapped to
all protein domains, demonstrating that mutations located
outside the catalytic domain can also disturb enzyme
function.
In summary, the results of thermal denaturation show
that mutations in the PAH gene lead to substantial distor-
tion of the protein’s conformation, with particular impact
on the regulatory domain.
Local Amino Acid Replacements Can Affect Networks
of Amino Acid Interactions
We constructed a composite 3D model of the full-length
PAH tetramer and performed 3D structural modeling.
Side-chain interactions in the local environment of amino
acid residues affected by mutations in our patients were
analyzed in order to investigate whether these amino
acid residues are directly or indirectly involved in networks
of side-chain interactions with functional and conforma-
tional impact. Our observations indicate that local amino
acid replacements can induce global conformational
changes, with remote effects on enzyme function and
stability of the PAH.
Figure 3. PAH Mutations Lead to Accelerated Thermal
Unfolding and Early Thermal Inactivation for Some Variants
(A–C) Thermal-unfolding profiles of wild-type and variant PAH
monitored by ANS fluorescence. Intensities of the fluorescent
dye ANS, which binds to hydrophobic groups of the protein
presented upon unfolding, are plotted as a function of increasing
temperatures. Error bars represent the mean5 SEM of three inde-
pendent experiments. The resulting denaturation curves consist of
three segments: a native baseline and two partially overlapping
phase transitions corresponding to unfolding of the regulatory
domain (first transition) and of the catalytic domain (second tran-
sition), respectively. Ground-state ANS fluorescence was markedly
elevated for I65S and A300S, indicating increased protein areas
available for dye binding. I65S lacked the first transition; all other
variants showed a left-shift of the first transition, indicating a
destabilization of the regulatory domain in comparison to the
wild-type. The second transition was not affected. R denotes reg-
ulatory domain; C denotes catalytic domain; O denotes oligomeri-
zation domain.
(D) Time course of thermal inactivation of wild-type and variant
PAH. Proteins were incubated at increasing temperatures, and
the residual enzyme activities were determined. Data points of re-
sidual activities were normalized to the initial enzyme activity and
subjected to nonlinear regression analysis. For three variants that
mapped to all domains (I65S, P314S, and Y417H), curves were left-
shifted in comparison to the wild-type. The remaining five variants
showed inactivation profiles comparable to that of wild-type PAH.The American Journal of Human Genetics 83, 5–17, July 2008 11
Table 4. Transition Midpoints and Midpoints of Thermal Inactivation for Thermal Denaturation of Wild-Type and Variant PAH
ANS Fluorescence Thermal Inactivation
Protein Domain Affected Missense Mutation tm1/2 SEM p Value tm2/3 SEM p Value Missense Mutation Tm SEM p Value
- WT 47.0 0.03 54.8 0.30 WT 48.85 0.52
R F55L 43.7 0.57 0.004 54.5 0.03 ns F55L 47.96 0.72 ns
R I65S - - - 53.9 0.30 ns I65S 46.17 0.56 0.042
- WT 47.0 0.52 55.1 0.30
C H170Q 46.1 0.00 ns 55.4 0.52 ns H170Q 48.92 0.20 ns
C P275L 44.1 0.52 0.029 54.6 0.05 ns P275L 48.40 0.76 ns
C A300S 44.6 0.30 0.016 54.5 0.03 ns A300S 49.46 0.61 ns
C P314S 44.9 0.60 ns 54.5 0.03 ns P314S 44.50 1.05 0.021
- WT 47.9 0.52 55.1 0.30
O Y414C 43.1 0.30 0.001 54.5 0.03 ns Y414C 48.42 0.43 ns
O Y417H 41.9 0.30 0.001 55.4 0.03 ns Y417H 44.99 0.21 0.011
- WT (mean) 47.3 0.26 55.0 0.16
Transition midpoints and midpoints of thermal inactivation obtained by thermal denaturation of wild-type PAH were compared to variants arising from
mutations in the regulatory (R), catalytic (C), and the oligomerization (O) domain. For ANS-fluorescence three sets of experiments covering the mutations
of different domains were carried out separately. The transition midpoints of the first (tm1/2) and the second transitions (tm2/3) were calculated by dif-
ferentiation of the increasing part of the curves and are given in C as means5 SEM of n ¼ 3 independent experiments. For thermal inactivation residual
activities were subjected to nonlinear regression analysis and the midpoints of thermal inactivation (Tm) were calculated. Tm-values representing the
temperature at 50% residual activity are given in C as means 5 SEM of quadruplicate assays in n ¼ 2 independent experiments. Significances for the
differences between wild-type and the variants were calculated by two-tailed Student’s t test.F55 and I65 are part of the hydrophobic core of the reg-
ulatory domain.Whereas F55L showed no impact on tetra-
mer assembly, I65S displayed disturbed oligomerization,
with increased amounts of dimeric protein in comparison
to the wild-type (Figure 2). The assembly of dimers to tetra-
meric PAH is promoted by coiled-coil interactions of the
C-terminal ahelices,7 which are preceded by two antiparallel
strands forming a b ribbon that comprises the dimerization
motif (residues 411–427).15,17 This b ribbon interacts with
the regulatory domain in the same subunit and with the
catalytic domain in the adjacent subunit within the dimer
(Figures 4A–4D). The electrostatic interactions of D415 and
E422 with R71 located in the prominent loop 68–75 play
a pivotal role for the proper position of the dimerization
motif, resulting in the right orientation of the a-helical
tetramerization motif for correct tetramer assembly. A dis-
tortion of the hydrophobic packing in the regulatory do-
main due to a substitution of the hydrophobic isoleucine
by the polar serine at position 65 is supposed to lead to
a displacement of the loop 68–75.10 Hence, an alteration
of the interaction of this loop with the dimerization motif
might lead to dislocation of the a-helical tetramerization
motif and result in altered oligomerization with increased
amounts of dimers.
Two of the PAH variants located in the catalytic domain
(S310Y and R408W) were exclusively puriﬁed as high-
molecular-weight aggregates lacking all residual enzyme ac-
tivity (Table 1 and Figure 2). Formation of aggregates was
previously described for R408W and structurally explained
by potential disruption of hydrogen bonding to L308 and
L311.7,8 The S310 residue builds a hydrogen bond to G307,
which interacts with L311. We thus inferred that both
S310 and R408 are part of a hydrogen-bonding network
formed by G307, L308, S310, L311, and R408 (Figures 4B12 The American Journal of Human Genetics 83, 5–17, July 2008and 4C). The R408 residue is located between two proline
residues, which deﬁne a sharp turn preceding the dimeriza-
tion motif. This hinge region anchors the oligomerization
domain to the catalytic domain and thereby ensures its
proper orientation. A disruption of the network by the
nonconservative substitutions S310Y and R408W could
therefore well induce severe distortion of the protein’s
oligomeric state.
P314 adopts a central position in a network that com-
prises residues of the regulatory and the catalytic domain
(Figure 4C). There is only one direct interaction between
the backbone carbonyl of P314 and the backbone amide
of Y317. However, the P314 residue is located in a loop (res-
idues 311–314) connecting a helices Ca8 and Ca9 that
deﬁne the active site. The neighboring residues D315 and
A313 form a network of interactions with R252 near the
pterin-binding loop (residues 248–251), with K113 in the
regulatory domain, and with D27 in the autoregulatory
sequence. Thus, local changes of the protein conformation
in the neighborhood of P314 could induce structural
changes at the active site, at the pterin-binding site, and
in the regulatory domain. This is in line with the observa-
tion that the variant P314S affected various enzyme kinetic
parameters with low residual activity, loss of activation,
and reduced cooperativity.
Y414C and Y417H, the variants arising from mutations
mapping to the oligomerization domain, surprisingly ex-
hibited clearly different oligomerization patterns although
they are located in close proximity to each other. Both res-
idues are part of the dimerization motif (Figure 4D). Y414
interacts with the catalytic domain of the same subunit,
whereas Y417 is located at the interface of monomer-
monomer interactions in the dimer, where it builds a net-
work with T238, R261, and Q304 of the adjacent subunit.
Figure 4. Amino Acid Residues Affected by PAH Mutations Are Involved in Functional Networks of Side-Chain Interactions
Selected parts of subunit backbones are shown as ribbon representations, and selected residues are depicted as stick models with carbon
atoms in white, oxygen atoms in red, and nitrogen atoms in blue. Hydrogen bonds are shown as golden dotted lines.
(A) Residues F55 and I65 are located in the hydrophobic core of the regulatory domain (subunit A, blue) followed by the prominent loop
68–75. Upon substrate activation, R68 builds a hydrogen bond to C237 in the catalytic domain of the adjacent monomer (subunit D, red).
R71 establishes electrostatic interactions with D415 and E422 in the dimerization motif, followed by coiled-coil interaction of the
tetramerization motif with the adjacent dimer (subunit B, yellow). The electrostatic interactions are supposed to hold the b-ribbon
in its proper spatial position resulting in the right orientation of the a-helical tetramerization motif.
(B) Residues S310 and R408 are both part of a hydrogen-bonding network that anchors the entire oligomerization domain to the catalytic
domain within one subunit. The coiled-coil interaction of subunits A (blue) and B (yellow) of both dimers contributes to tetramer
assembly. R408 builds hydrogen bonds to the main-chain carbonyl oxygens of L308 and L311 located in the active-site helix Ca8.
S310 contributes to this network through interaction with G307 that builds a hydrogen bond to the main-chain amide of L311.
(C) P314 is part of the loop 311–314 connecting a helices Ca8 and Ca9 that define the bottom of the active site. The network of R252,
A313, P314, D315, and Y317 contributes to the correct spatial orientation of the active site and the pterin-binding loop 248–251. It is
expanded via interaction with residues D27, located in the intrinsic autoregulatory sequence (1–33), and K113, located in a hinge-bend-
ing region (111–117) connecting the catalytic to the regulatory domain. This area is in close proximity to the network comprising
residues S310 and R408 (B), which constitutes the connection of the whole region with the dimerization motif of the oligomerization
domain. BH4 at the active site is shown as an orange stick model.
(D) Y414 and Y417 are located in a loop connecting two antiparallel b strands forming the dimerization motif. Y417 joins a network
comprising residues Q304, R261, and T238, which tightly links the dimerization motif to the catalytic domain of the adjacent subunit
(subunit A, blue; subunit D, red). The hydroxyl group of Y417 builds a hydrogen bond to Q304, and the aromatic ring of Y417 stacks
with the positively charged guanidinium group of R261. Q304 and T238 are connected to R261 via hydrogen bonds. Y414 is localized
in close proximity to residue Y417 but does not contribute to the monomer-monomer interaction.The American Journal of Human Genetics 83, 5–17, July 2008 13
Y417H is supposed to disrupt the hydrogen bond to Q304
and to damage the polar p stacking due to repulsions
between the histidine and the positively charged guanidi-
nium group of R261. This would result in hindrance of
dimer formation with the appearance of monomers, and,
as a consequence, disturbed tetramerization.
Taken together, the results of the in silico structural
analysis of this subset of variants support the notion that
local replacement of an amino acid at one site can disturb
amino acid networks and, as a consequence, induce global
changes in conformation that also affect remote parts of
the protein at the functional level.
Discussion
Despite the severe clinical phenotype of PKU, many
missense mutations in the PAH gene have previously
been shown to be associated with surprisingly high resid-
ual enzyme activities in vitro. It therefore has to be antici-
pated that mutations lead to loss of function through
mechanisms other than impaired catalysis. Previous stud-
ies reported on PAH protein aggregation and rapid degra-
dation,3,4,18,39 raising the hypothesis that aberrant folding
is a consequence of PAH mutations. Recent work substan-
tiated this hypothesis, providing predictions about the
effect of PAHmutations on native-state-protein stability.23
Here, we present several lines of experimental evidence
that support the hypothesis that PAH missense mutations
associated with the newly recognized clinical phenotype of
BH4-responsive PAH deﬁciency lead to protein misfolding.
Two mutations (S310Y and R408W) caused severe struc-
tural distortion, with protein aggregation and complete
loss of enzyme function. The others showed milder alter-
ations of conformation but were associated with impaired
enzyme-kinetic parameters, oligomerization, and protein
stability at different degrees. Moreover, we showed that
PAHmutations not only have an impact on the local struc-
tural environment of the affected side chain but rather
induce alterations consistent with distortion of the
enzyme’s global conformation.
Interestingly, all variant PAH proteins analyzed in our
study showed disturbed regulation. Allostery in general
and PAH allostery in particular are complex events in
which numerous side-chain interactions transmit struc-
tural changes throughout the whole oligomer. Extensive
previous work has deﬁned speciﬁc sites that are involved
in PAH allostery.12,15,34 Allosteric conformational changes
in substrate binding result not only in positive cooperativ-
ity but also in activation of the enzyme. We observed that
all but one variant led to reduced cooperativity, and six
mutations that mapped to all three domains induced a
loss of substrate activation. This led us to assume that
mutations affecting sites involved in allostery cause a cas-
cade of structural consequences, with alteration of confor-
mational ﬂexibility. As a result, remote functional units of
side-chain interactions could be disturbed. Indeed, we ob-14 The American Journal of Human Genetics 83, 5–17, July 2008served a negative impact of the I65S mutation located in
the regulatory domain on the tetramer-dimer equilibrium.
On a structural level, this can be explained by the multiple
interactions required for PAH oligomerization that are not
limited to the oligomerization domains but also involve
allosteric contacts of all domains.
Additional evidence for protein misfolding arose from
results demonstrating destabilization of variant PAH
against proteolytic attack by proteinase K. In general, mis-
folded or partly unfolded proteins show enhanced back-
bone ﬂexibility and thus facilitate proteolytic attack.36
Results from limited proteolysis pointed to altered folding
of the N-terminal regulatory domain. Moreover, mutations
located on the protein surface (H170Q, P275L) were shown
to be particularly prone to proteolytic attack, whereas
mutations buried in the core of the protein (F55L, I65S,
Y417H) were not. Direct experimental evidence for alter-
ations in global protein conformation arose from the anal-
ysis of PAH hydrophobicity in the ground state and during
thermal denaturation. Presentation of hydrophobic groups
at the variant protein’s surface caused by protein misfold-
ing facilitates binding of the ANS ﬂuorophore. Indeed, an
increase in ANS ﬂuorescence in the ground state was
observed for the two mutations in the regulatory domain
and for most mutations in the catalytic domain. Interest-
ingly, all variant PAH showed accelerated thermal unfold-
ing. Furthermore, our investigations revealed that inde-
pendent of the position of the affected residue, PAH
mutations had the most impact on the unfolding of the
regulatory domain. This was conﬁrmed by analysis of the
inactivation of enzyme function by thermal stress. Only
three mutations led to accelerated thermal inactivation
(I65S, P314S, Y417H); among these, just one mapped to
the catalytic domain. Altogether, data from stability assays
indicate that the structural conformation of the PAH regu-
latory domain is particularly unstable. This observation
can be explained by the structural characteristics of this
domain. Recently, Liberles et al. provided strong evidence
that the regulatory domain of PAH comprises an evolu-
tionary mobile regulatory module, the ACT domain.12 It
facilitates allosteric regulation via transmission of ﬁnely
tuned conformational changes, a process that appears to
be set by the regulatory domains’ interactions with the
partner domains. These interactions require a high degree
of conformational ﬂexibility. For PAH isolated from a cold-
adapted organism, it was shown that an increase in confor-
mational ﬂexibility is accompanied by an increase in ther-
molability.40 Thus, the mobility of the regulatory domain
that allows for complex regulation of activity and the olig-
omeric state might on the other hand cause reduced stabil-
ity against thermal stress and proteolytic attack. Moreover,
the extensive networking of the regulatory domain with
other parts of the protein could account for the adoption
of misfolding from remote sites. By contrast, missense
mutations, if not structurally disruptive, hardly affected
the integrity of the catalytic domain. This was shown by
unchanged patterns of thermal unfolding of the catalytic
domain and further supported by the variant’s high resid-
ual enzyme activity and minor changes in thermal-inacti-
vation experiments. The domain’s dense tertiary structure
with few ﬂexible regions could be the reason for these
observations.
Taken together, the results presented here indicate that
PAH missense mutations can lead to protein misfolding
and conformational destabilization at different degrees.
Our ﬁndings are in agreement with recent results from
computational analyses using the FoldX algorithm. This
study showed that a signiﬁcant share of a large set of
PAHmutations is predicted to provoke protein misfolding.
Moreover, the authors raised the hypothesis that residues
buried in the 3D structure, unlike those in ﬂexible regions,
are particularly prone to severe misfolding.23 Our ﬁndings
conﬁrm this at the experimental level for a subset of ten
mutations identiﬁed in patients with BH4-responsive
PAH deﬁciency. Mutations at the center of the protein
structure (S310Y, R408W) were shown to lead to severe ag-
gregation and complete disruption of structural integrity.
Conversely, mutations in ﬂexible regions of the protein
(H170Q, P275L, P314S, Y417H) did not primarily show
severe protein misfolding. However, they can indeed cause
milder conformational changes, which still exert deleteri-
ous effects on enzyme function. Features like oligomeriza-
tion, allostery, activation, and cooperativity need complex
conformational rearrangements, which are communicated
through ﬂexible regions of the protein via networks of
amino acid interactions. Our observations imply that mu-
tations, even those in ﬂexible protein regions, can severely
affect enzyme function and stability if they directly or in-
directly disrupt these networks. In addition to our results
from naturally occurring mutations, this was previously
shown by analysis of artiﬁcial mutations of amino acid res-
idues in ﬂexible hinge-bending regions. These are involved
in substrate-triggered molecular motions, and the corre-
sponding proteins showed a reduced conformational sta-
bility in comparison to that of wild-type PAH.13 Finally,
two observations exemplify that there also appears to be
no general rule for missense mutations of buried residues
leading to severe misfolding with protein destabilization
and impaired enzyme function. Both A300 and P314 are
located in the active center of the protein; A300 is part of
helix Ca8, which together with helix Ca9 deﬁnes the
catalytic core, whereas P314 lies in a ﬂexible loop between
helices Ca8 and Ca9. A300S led to conformational desta-
bilization, with distinct proneness to proteinase K and
elevated ground-state ANS ﬂuorescence. Nonetheless, en-
zyme function remained virtually unaffected. Conversely,
P314S showing a clear stabilization toward proteinase K
led to a marked reduction in enzyme activity and to accel-
erated thermal inactivation.
The results from our experimental work revealed that
PAH misfolding is probably communicated throughout
the protein by disruption of functionally crucial networks
of amino acid interactions. Thus, the classical domain-as-
sociated view of mutational effects on the protein mightbe insufﬁcient for understanding of the molecular pheno-
type, and it disregards the well-known complexity in
structure and regulation of the PAH protein.15,37 We there-
fore propose a view of PAH that not only considers three
primary-structure domains but takes into account that
the PAH enzyme is an entity of functional units that arise
from the tertiary and quaternary protein structure. If this
holds true, mutations in the PAH gene exert their effects
by disturbance of these functional units.
PKU has evolved from a model of a genetic disease that
leads to severe neurologic impairment to amodel of a treat-
able protein-folding disease with loss of function. The new
insights into molecular mechanisms of protein misfolding
are a prerequisite for the unraveling of how the natural co-
factor BH4 corrects the biochemical consequences of PAH
gene mutations and will help treatment of patients on an
individually tailored basis.
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